OBJECTIVES: Development of a simple and accurate technique for detecting active inflammation in the joints and other tissues of patients with inflammatory disorders is an unmet need in rheumatic diseases. This study is a preliminary assessment of the safety and usage of a radiopharmaceutical, FolateScan (Technetium-99m EC20; 99mTc-EC20), for detecting disease activity in patients with rheumatoid arthritis. METHODS: EC20 is a folate-targeted diagnostic radiopharmaceutical which binds to the folate receptor and is preferentially taken up by activated macrophages. In this open-label, cross-sectional study, a total of 40 patients with RA (26 with one or more swollen joints, 14 with clinically quiescent joint disease; 0/66 joint count) as well as 6 patients with osteoarthritis, 12 patients with other inflammatory conditions and 5 healthy subjects received 0.1 mg of EC20 labeled with 20-25mCi of technetium-99m. Disease activity was scored in each joint and other target tissues by a radiologist blinded to the clinical assessment, and results were compared to the rheumatologist's physical examination, which served as the test standard. RESULTS: The 40 patients (78% female) with RA had a mean age of 56.9 years. Assessment of uptake of 99mTc-EC20 in joints of patients with RA based on image analysis was compared to the clinical examination. FolateScan detected more actively involved joints in 27 patients (68%) than joints recorded as "swollen", and more actively involved joints in 25 patients (63%) than joints recorded as "painful and/or swollen". The number of swollen joints by clinical exam was correlated with ESR (r=0.43; p=0.006) and C-rp (r=0.35; p=0.03). The number of actively involved joints by FolateScan was also correlated with ESR (r=0.47; p=0.002) and C-rp (r=0.36; p=0.02). Joint uptake was also seen in patients with osteoarthritis. CONCLUSION: FolateScan is a potentially useful tool for detection of disease activity in patients with RA and may be more sensitive than the physical examination.
OBJECTIVES: Development of a simple and accurate technique for detecting active inflammation in the joints and other tissues of patients with inflammatory disorders is an unmet need in rheumatic diseases. This study is a preliminary assessment of the safety and usage of a radiopharmaceutical, FolateScan (Technetium-99m EC20; 99mTc-EC20), for detecting disease activity in patients with rheumatoid arthritis. METHODS: EC20 is a folate-targeted diagnostic radiopharmaceutical which binds to the folate receptor and is preferentially taken up by activated macrophages. In this open-label, cross-sectional study, a total of 40 patients with RA (26 with one or more swollen joints, 14 with clinically quiescent joint disease; 0/66 joint count) as well as 6 patients with osteoarthritis, 12 patients with other inflammatory conditions and 5 healthy subjects received 0.1 mg of EC20 labeled with 20-25mCi of technetium-99m. Disease activity was scored in each joint and other target tissues by a radiologist blinded to the clinical assessment, and results were compared to the rheumatologist's physical examination, which served as the test standard. RESULTS: The 40 patients (78% female) with RA had a mean age of 56.9 years. Assessment of uptake of 99mTc-EC20 in joints of patients with RA based on image analysis was compared to the clinical examination. FolateScan detected more actively involved joints in 27 patients (68%) than joints recorded as "swollen", and more actively involved joints in 25 patients (63%) than joints recorded as "painful and/or swollen". The number of swollen joints by clinical exam was correlated with ESR (r=0.43; p=0.006) and C-rp (r=0.35; p=0.03). The number of actively involved joints by FolateScan was also correlated with ESR (r=0.47; p=0.002) and C-rp (r=0.36; p=0.02). Joint uptake was also seen in patients with osteoarthritis. CONCLUSION:FolateScan is a potentially useful tool for detection of disease activity in patients with RA and may be more sensitive than the physical examination.
Authors: Mary Jo Turk; Gert J Breur; William R Widmer; Chrystal M Paulos; Le-Cun Xu; Lee Ann Grote; Philip S Low Journal: Arthritis Rheum Date: 2002-07
Authors: L T Mantovani; S Miotti; S Ménard; S Canevari; F Raspagliesi; C Bottini; F Bottero; M I Colnaghi Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Ronald E Fisher; Barry A Siegel; Steven L Edell; Nelson M Oyesiku; David E Morgenstern; Richard A Messmann; Robert J Amato Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: V B Kraus; G McDaniel; J L Huebner; T V Stabler; C F Pieper; S W Shipes; N A Petry; P S Low; J Shen; T A McNearney; P Mitchell Journal: Osteoarthritis Cartilage Date: 2016-04-12 Impact factor: 6.576
Authors: Yingjuan Lu; Nikki Parker; Paul J Kleindl; Vicky A Cross; Kristin Wollak; Elaine Westrick; Torian W Stinnette; Mark A Gehrke; Kevin Wang; Hari Krishna R Santhapuram; Fei You; Spencer J Hahn; Jeremy F Vaughn; Patrick J Klein; Iontcho R Vlahov; Philip S Low; Christopher P Leamon Journal: Mol Med Date: 2015-07-08 Impact factor: 6.354
Authors: Marleen van Oosten; Lucia Ma Crane; Joost Bart; Fijs W van Leeuwen; Gooitzen M van Dam Journal: Transl Oncol Date: 2011-04-01 Impact factor: 4.243
Authors: Jiayin Shen; Andrew R Hilgenbrink; Wei Xia; Yang Feng; Dimiter S Dimitrov; Michael B Lockwood; Robert J Amato; Philip S Low Journal: J Leukoc Biol Date: 2014-07-11 Impact factor: 4.962
Authors: Yoony Y J Gent; Karin Weijers; Carla F M Molthoff; Albert D Windhorst; Marc C Huisman; Desirée E C Smith; Sumith A Kularatne; Gerrit Jansen; Philip S Low; Adriaan A Lammertsma; Conny J van der Laken Journal: Arthritis Res Ther Date: 2013-03-01 Impact factor: 5.156